Department of Immunology, Weizmann Institute of Science, Rehovot
Hematology Department, Meir Medical Center, Kfar Saba.
Haematologica. 2019 May;104(5):872-880. doi: 10.3324/haematol.2018.195289. Epub 2019 Apr 19.
The ontogeny of acute myeloid leukemia is a multistep process. It is driven both by features of the malignant clone itself as well as by environmental pressures, making it a unique process in each individual. The technological advancements of recent years has increased our understanding about the different steps that take place at the genomic level. It is now clear that malignant clones evolve, expand and change even during what seem to be clinically healthy or "cured" periods. This opens a wide window for new therapeutic and monitoring opportunities. Moreover, prediction and even early prevention have become possible goals to be pursued. The aim of this review is to shed light upon recent observations in leukemia evolution and their clinical implications. We present a critical view of these concepts in order to assist clinicians when interpreting results of the ever growing myriad of genomic diagnostic tests. We wish to help clinicians incorporate genetic tests into their clinical assessment and enable them to provide genetic counseling to their patients.
急性髓系白血病的发生是一个多步骤的过程。它不仅受到恶性克隆本身的特征的驱动,还受到环境压力的影响,因此在每个个体中都是一个独特的过程。近年来的技术进步提高了我们对基因组水平上发生的不同步骤的理解。现在很明显,即使在看似临床健康或“治愈”的时期,恶性克隆也会进化、扩张和改变。这为新的治疗和监测机会开辟了广阔的空间。此外,预测甚至早期预防已成为可能追求的目标。本综述的目的是阐明白血病进化的最新观察结果及其临床意义。我们对这些概念进行了批判性的分析,以便在解释不断增长的基因组诊断测试结果时为临床医生提供帮助。我们希望帮助临床医生将遗传测试纳入他们的临床评估,并使他们能够为他们的患者提供遗传咨询。